Evaxion A/S announced new three-year clinical outcome data from its phase 2 trial evaluating the personalized cancer vaccine EVX-01 in patients with advanced melanoma. The findings show that all ...

Oculis announces completion of enrollment in PREDICT-1 trial for Licaminlimab, targeting precision treatment for dry eye ...

Oculis completes patient enrollment in Licaminlimab trial for dry eye disease, targeting a specific genetic variant linked to ...

Red Cat Holdings proposes to acquire Steyr Motors for EUR 39.00 per share, enhancing defense capabilities and growth ...

Beyer criticizes East Potomac Park project: Rep. Don Beyer said President Trump’s announcement about East Potomac Park ...

Blocksight's AI agents will automate processes like deal structuring, asset verification, and investor reporting within OpenWorld's platform. Key projects include a $1 billion tokenized financing ...

Van Drew says ICE confirmed suspect status: Congressman Jefferson Van Drew said U.S. Immigration and Customs Enforcement and ...

Roundtable on wildfire technology: Rep. Young Kim said she convened federal, state and local firefighting agencies, policy ...

Eikon Therapeutics presents updates on its oncology pipeline at the 2026 ESMO Congress, highlighting several clinical studies ...

Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients indicates promising efficacy of azenosertib monotherapy. The data will be presented at a major ...

The APOLLO Phase 3 trial evaluates the efficacy of bitopertin for treating erythropoietic porphyrias (EPP). The corporate webcast will be held on Monday, October 19, 2026, at 8:00 a.m. ET. You can ...

Speaker Johnson interview highlights: Speaker Mike Johnson spoke with CBS News’ Robert Costa during a visit to Louisiana’s ...